Immunogenicity of a polyvalent HIV-1 candidate vaccine based on fourteen wild type gp120 proteins in golden hamsters

BMC Immunology

Volumn 7, Issue , 2006, Pages

  Azizi, Ali ^a,b   Anderson, David E ^b,c   Ghorbani, Masoud ^b   Gee, Katrina ^a,b   Diaz Mitoma, Francisco ^a,b  

^a CHILDREN S HOSPITAL OF EASTERN ONTARIO   (Canada)

^b Variation Biotechnologies Inc   (Canada)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN GP 120; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; NEUTRALIZING ANTIBODY; PHOSPHORYL LIPID A;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CELL PROLIFERATION; CELLULAR IMMUNITY; CHO CELL; CONTROLLED STUDY; CROSS REACTION; DRUG FORMULATION; FEMALE; GENE AMPLIFICATION; HAMSTER; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; MALE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN PURIFICATION; PROTEIN STRUCTURE; STRAIN DIFFERENCE; SYNCYTIUM; VIRUS IMMUNITY; VIRUS ISOLATION; WILD TYPE;

AIDS VACCINES; AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, VIRAL; ANTIBODY FORMATION; CELL PROLIFERATION; CHO CELLS; CRICETINAE; DNA, VIRAL; FEMALE; HIV ENVELOPE PROTEIN GP120; HIV-1; HUMANS; IMMUNIZATION; MALE; MESOCRICETUS; MOLECULAR SEQUENCE DATA; NEUTRALIZATION TESTS; PHYLOGENY; SEQUENCE ALIGNMENT; T-LYMPHOCYTES;

EID: 33751120934     PISSN: 14712172     EISSN: 14712172     Source Type: Journal    
DOI: 10.1186/1471-2172-7-25     Document Type: Article

References (44)

1. Hotzel I, Cheevers WP: Caprine arthritis-encephalitis virus envelope surface glycoprotein regions interacting with the transmembrane glycoprotein: structural and functional parallels with human immunodeficiency virus type 1 gp 120. J Virlo 2003, 77:11578-11587.
2. Kim YB, Han DP, Cao C, Cho MW: Immunogenicity and ability of variable loop-deleted human immunodeficiency virus type 1 envelope glycoproteins to elicit neutralizing antibodies. Virology 2003, 305:124-137.
3. Grundner C, Pancera M, Kang JM, Koch M, Sodroski J, Wyatt R: Factors limiting the immunogenicity of HIV-1 gp 120 envelope glycoproteins. Virology 2004, 330:233-248.
4. Kwong PD, Wyatt R, Majeed S, Robinson J, Sweet RW, Sodroski J, Hendrickson WA: Structures of HIV-1 gp 120 envelope glycoproteins from laboratory-adapted and primary isolates. Structure Fold Des 2000, 8:1329-1339.
5. Wyatt R, Kwong PD, Desiardins E, Sweet RW, Robinson J, Hendrickson WA, Sodroski JG: The antigenic structure of the HIV gp 120 envelope glycoprotein. Nature 1998, 393:705-711.
6. Kandathil AJ, Ramalingam S, Kannangai R, David S, Sridharan G: Molecular epidemiology of HIV. Indian J Med Res 2005, 121:333-344.
7. Choisy M, Woelk CH, Guegan JF, Robertson DL: Comparative study of adaptive molecular evolution in different human immunodeficiency virus groups and subtypes. J Virol 2004, 78:1962-1970.
8. Ciurea A, Klenerman P, Hunziker L, Horvath E, Senn BM, Ochsenbein AF, Hengartner H, Zinkernagel RM: Viral persistence in vivo through selection of neutralizing antibody-escape variants. Proc Natl Acad Sci U S A 2000, 97:2749-2754.
9. Leung L, Srivastava IK, Kan E, Legg H, Sun Y, Greer C, Montefiori DC, zur MJ, Barnett SW: Immunogenicity of HIV-1 Env and Gag in baboons using a DNA prime/protein boost regimen. AIDS 2004, 18:991-1001.
10. Johnston R: AIDSVAX results: an answer, or just more questions? AIDS Patient Care STDS 2003, 17:47-51.
11. Billich A: AIDSVAX VaxGen. Curr Opin Investig Drugs 2001, 2:1203-1208.
12. Billich A: AIDSVAX VaxGen. Curr Opin Investig Drugs 2004, 5:214-221.
13. Montefiori DC: Neutralizing antibodies take a swipe at HIV in vivo. Nat Med 2005, 11:593-594.
14. Sato H, Kato K, Takebe Y: Functional complementation of the envelope hypervariable V3 loop of human immunodeficiency virus type 1 subtype B by the subtype E V3 loop. Virology 1999, 257:491-501.
15. Hu DJ, Vanichseni S, Mastro TD, Raktham S, Young NL, Mock PA, Subbarao S, Parekh BS, Srisuwanvilai L, Sutthent R, Wasi C, Heneine W, Choopanya K: Viral load differences in early infection with two HIV-1 subtypes. AIDS 2001, 15:683-691.
16. Ferrantelli F, Rasmussen RA, Hofmann-Lehmann R, Xu W, McClure HM, Ruprecht RM: Do not underestimate the power of antibodies-lessons from adoptive transfer of antibodies against HIV. Vaccine 2002, 20 Suppl 4:A61-A65.
17. Nishimura Y, Igarashi T, Haigwood NL, Sadjadpour R, Donau OK, Buckler C, Plishka RJ, Buckler-White A, Martin MA: Transfer of neutralizing IgG to macaques 6 h but not 24 h after SHIV infection confers sterilizing protection: implications for HIV-1 vaccine development. Proc Natl Acad Sci U S A 2003, 100:15131-15136.
18. Rasmussen RA, Hofmann-Lehmann R, Li PL, Vlasak J, Schmitz JE, Reimann KA, Kuroda MJ, Letvin NL, Montefiori DC, McClure HM, Ruprecht RM: Neutralizing antibodies as a potential secondary protective mechanism during chronic SHIV infection in CD8+ T-cell-depleted macaques. AIDS 2002, 16:829-838.
19. Krachmarov CP, Kayman SC, Honnen WJ, Trochev O, Pinter A: V3-specific polyclonal antibodies affinity purified from sera of infected humans effectively neutralize primary isolates of human immunodeficiency virus type 1. AIDS Res Hum Retroviruses 2001, 17:1737-1748.
20. Inouye P, Cherry E, Hsu M, Zolla-Pazner S, Wainberg MA: Neutralizing antibodies directed against the V3 loop select for different escape variants in a virus with mutated reverse transcriptase (M184V) than in wild-type human immunodeficiency virus type 1. AIDS Res Hum Retroviruses 1998, 14:735-740.
21. Wei X, Decker JM, Wang S, Hui H, Kappes JC, Wu X, Salazar-Gonzalez JF, Salazar MG, Kilby JM, Saag MS, Komarova NL, Nowak MA, Hahn BH, Kwong PD, Shaw GM: Antibody neutralization and escape by HIV-1. Nature 2003, 422:307-312.
22. Wang FX, Kimura T, Nishihara K, Yoshimura K, Koito A, Matsushita S: Emergence of autologous neutralization-resistant variants from preexisting human immunodeficiency virus (HIV) quasi species during virus rebound in HIV type 1-infected patients undergoing highly active antiretroviral therapy. J Infect Dis 2002, 185:608-617.
23. Chen CH, Jin L, Zhu C, Holz-Smith S, Matthews TJ: Induction and characterization of neutralizing antibodies against a human immunodeficiency virus type 1 primary isolate. J Virol 2001, 75:6700-6704.
24. Schreiber M, Wachsmuth C, Muller H, Odemuyiwa S, Schmitz H, Meyer S, Meyer B, Schneider-Mergener J: The V3-directed immune response in natural human immunodeficiency virus type 1 infection is predominantly directed against a variable, discontinuous epitope presented by the gp 120 V3 domain. J Virol 1997, 71:9198-9205.
25. Yamaguchi-Kabata Y, Yamashita M, Ohkura S, Hayami M, Miura T: Linkage of amino acid variation and evolution of human immunodeficiency virus type 1 gp 120 envelope glycoprotein (subtype B) with usage of the second receptor. J Mol Evol 2004, 58:333-340.
26. Jensen MA, Li FS, 't Wout AB, Nickle DC, Shriner D, He HX, McLaughlin S, Shankarappa R, Margolick JB, Mullins JI: Improved coreceptor usage prediction and genotypic monitoring of R5-to-X4 transition by motif analysis of human immunodeficiency virus type 1 env V3 loop sequences. J Virol 2003, 77:13376-13388.
27. Srivastava IK, Ulmer JB, Barnett SW: Neutralizing antibody responses to HIV: role in protective immunity and challenges for vaccine design. Expert Rev Vaccines 2004, 3:S33-S52.
28. Li M, Gao F, Mascola JR, Stamatatos L, Polonis VR, Koutsoukos M, Voss G, Goepfert P, Gilbert P, Greene KM, Bilska M, Kothe DL, Salazar-Gonzalez JF, Wei X, Decker JM, Hahn BH, Montefiori DC: Human Immunodeficiency Virus Type 1 env Clones from Acute and Early Subtype B Infections for Standardized Assessments of Vaccine-Elicited Neutralizing Antibodies. J Virol 2005, 79:10108-10125.
29. Sarmati L, d'Ettorre G, Nicastri E, Ercoli L, Uccella I, Massetti P, Parisi SG, Vullo V, Andreoni M: Neutralizing antibodies against autologous human immunodeficiency virus Type 1 isolates in patients with increasing CD4 cell counts despite incomplete virus suppression during antiretroviral treatment. Clin Diagn Lab Immunol 2001, 8:822-824.
30. Locher CP, Grant RM, Collisson EA, Reyes-Teran G, Elbeik T, Kahn JO, Levy JA: Antibody and cellular immune responses in breakthrough infection subjects after HIV type 1 glycoprotein 120 vaccination. AIDS Res Hum Retroviruses 1999, 15:1685-1689.
31. Zhan X, Martin LN, Slobod KS, Coleclough C, Lockey TD, Brown SA, Stambas J, Bonsignori M, Sealy RE, Blanchard JL, Hurwitz JL: Multi-envelope HIV-1 vaccine devoid of SIV components controls disease in macaques challenged with heterologous pathogenic SHIV. Vaccine 2005, 23:5306-5320.
32. Pal R, Wang S, Kalyanaraman VS, Nair BC, Whitney S, Keen T, Hocker L, Hudacik L, Rose N, Cristillo A, Mboudjeka I, Shen S, Wu-Chou TH, Montefiori D, Mascola J, Lu S, Markham P: Polyvalent DNA prime and envelope protein boost HIV-1 vaccine elicits humoral and cellular responses and controls plasma viremia in rhesus macaques following rectal challenge with an R5 SHIV isolate. J Med Primatol 2005, 34:226-236.
33. Leandersson AC, Gilljam G, Fredriksson M, Hinkula J, Alaeus A, Lidman K, Albert J, Bratt G, Sandstrom E, Wahren B: Cross-reactive T-helper responses in patients infected with different subtypes of human immunodeficiency virus type 1. J Virol 2000, 74:4888-4890.
34. Cho MW, Kim YB, Lee MK, Gupta KC, Ross W, Plishka R, Buckler-White A, Igarashi T, Theodore T, Byrum R, Kemp C, Montefiori DC, Martin MA: Polyvalent envelope glycoprotein vaccine elicits a broader neutralizing antibody response but is unable to provide sterilizing protection against heterologous Simian/human immunodeficiency virus infection in pigtailed macaques. J Virol 2001, 75:2224-2234.
35. Cavacini LA, Duval M, Patil A, Wood C, Mayer KH, Ruprecht RM, Posner MR: Dichotomy in cross-clade reactivity and neutralization by HIV-1 sera: implications for active and passive immunotherapy. J Med Virol 2005, 76:146-152.
36. Wang S, Pal R, Mascola JR, Chou TH, Mboudjeka I, Shen S, Liu Q, Whitney S, Keen T, Nair BC, Kalyanaraman VS, Markham P, Lu S: Polyvalent HIV-1 Env vaccine formulations delivered by the DNA priming plus protein boosting approach are effective in generating neutralizing antibodies against primary human immunodeficiency virus type 1 isolates from subtypes A, B, C, D and E. Virology 2006, 350:34-47.
37. Klein MR, Veenstra J, Holwerda AM, Roos MT, Gow I, Patou G, Coutinho RA, De Wolf F, Miedema F: Gag-specific immune responses after immunization with p17/p24:Ty virus-like particles in HIV type 1-seropositive individuals. AIDS Res Hum Retroviruses 1997, 13:393-399.
38. Currier JR, Dowling WE, Wasunna KM, Alam U, Mason CJ, Robb ML, Carr JK, McCutchan FE, Birx DL, Cox JH: Detection of high frequencies of HIV-1 cross-subtype reactive CD8 T lymphocytes in the peripheral blood of HIV-1-infected Kenyans. AIDS 2003, 17:2149-2157.
39. Pavlovic-Lazetic GM, Mitic NS, Beljanski MV: Bioinformatics analysis of SARS coronavirus genome polymorphism. BMC Bioinformatics 2004, 5:65.
40. Li KB: ClustalW-MPI: ClustalW analysis using distributed and parallel computing. Bioinformatics 2003, 19:1585-1586.
41. Ghorbani M, Nass T, Azizi A, Soare C, Aucoin S, Giulivi A, Anderson DE, Diaz-Mitorna F: Comparison of antibody- and cell-mediated immune responses after intramuscular hepatitis C immunizations of BALB/c mice. Virol Immunol 2005, 18:637-648.
42. Azizi A, Aucoin S, Tadesse H, Frost P. Ghorbani M, Soare C, Naas T, Diaz-Mitoma F: A combined nucleocapsid vaccine induces vigorous SARS-CD8+ T-cell immune responses. Genet Vaccines Ther 2005, 3:7.
43. Naas T, Ghorbani M, Alvarez-Maya I, Lapner M, Kothary R, De Repentigny Y, Gomes S, Babiuk L, Giulivi A, Soare C, Azizi A, Diaz-Mitoma F: Characterization of liver histopathology in a transgenic mouse model expressing genotype 1 a hepatitis C virus core and envelope proteins 1 and 2. J Gen Virol 2005, 86:2185-2196.
44. Azizi A, Ghorbani M, Kryworuchko M, Aucoin S, Diaz-Mitoma F: Potency of cell-mediated immune responses to different combined HIV-1 immunogens in a humanized murine model. Hum. Vaccin 2005, 1(4):170-176.